Arthrotec Articles
Celltech profits up 28% ex-restructuring
14 March 2001
China sees over-supply, low demand for drugs
16 March 2000
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Searle's Arthrotec Approved In USA
2 January 1998
Searle Reports Progress With COX-2 Inhibitor
21 October 1996
Yamanouchi To Develop Searle's Celecoxib In Japan
29 April 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
Many US Biotech Firms See Good 3rd Qtr Sales Growth
13 November 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Beleaguered Dutch Pharma Market Manages 5% Growth
21 August 1995
Arthrotec Overcomes NSAID Problems
26 September 1994
US CHEMICAL/DRUG COs SHOW 1st QTR GROWTH
9 May 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
NEW ARTHROTEC APPROVALS
13 December 1993
MISOPROSTOL PRAISED AT ILAR
26 July 1993
ROBERTS ACQUIRES SEARLE PRODUCTS
5 April 1993
1ST LAUNCH OF ARTHROTEC IN UK
8 February 1993
SEARLE'S ARTHROTEC APPROVED IN UK
22 June 1992
Showing 1-25 of 25 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
